Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.66% | 10.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.66% | 10.55% | |||
| Cost of Revenue | -67.69% | 167.27% | |||
| Gross Profit | 21.02% | 1.79% | |||
| SG&A Expenses | 0.42% | 21.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.76% | 29.09% | |||
| Operating Income | 95.34% | -1,251.32% | |||
| Income Before Tax | 104.29% | -633.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 104.20% | -650.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 104.20% | -650.31% | |||
| EBIT | 95.34% | -1,251.32% | |||
| EBITDA | 96.32% | -1,450.92% | |||
| EPS Basic | 103.84% | -570.74% | |||
| Normalized Basic EPS | 106.94% | -272.73% | |||
| EPS Diluted | 103.84% | -570.74% | |||
| Normalized Diluted EPS | 106.57% | -272.73% | |||
| Average Basic Shares Outstanding | 10.14% | 11.78% | |||
| Average Diluted Shares Outstanding | 14.03% | 11.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||